| Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, ... The Lancet Neurology 20 (7), 526-536, 2021 | 412 | 2021 |
| Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 … JF Howard, RJ Nowak, GI Wolfe, ML Freimer, TH Vu, JL Hinton, ... JAMA neurology 77 (5), 582-592, 2020 | 158 | 2020 |
| Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study V Bril, A Drużdż, J Grosskreutz, AA Habib, R Mantegazza, S Sacconi, ... The Lancet Neurology 22 (5), 383-394, 2023 | 128 | 2023 |
| Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study JF Howard, S Bresch, A Genge, C Hewamadduma, J Hinton, Y Hussain, ... The Lancet Neurology 22 (5), 395-406, 2023 | 119 | 2023 |
| Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised … V Granit, M Benatar, M Kurtoglu, MD Miljković, N Chahin, G Sahagian, ... The Lancet Neurology 22 (7), 578-590, 2023 | 106 | 2023 |
| Therapeutic strategies for diabetic neuropathy AA Habib, TH Brannagan Current neurology and neuroscience reports 10, 92-100, 2010 | 83 | 2010 |
| Varicella zoster virus meningitis with hypoglycorrhachia in the absence of rash in an immunocompetent woman AA Habib, D Gilden, DS Schmid, JE Safdieh Journal of neurovirology 15 (2), 206-208, 2009 | 57 | 2009 |
| Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study SA Rudnicki, JA Andrews, T Duong, BM Cockroft, FI Malik, L Meng, J Wei, ... Neurotherapeutics 18 (2), 1127-1136, 2021 | 51 | 2021 |
| Emerging drugs for amyotrophic lateral sclerosis AA Habib, H Mitsumoto Expert opinion on emerging drugs 16 (3), 537-558, 2011 | 51 | 2011 |
| Predictors of mortality in brain abscess HU Qureshi, AA Habib, AA Siddiqui, T Mozaffar, AR Sarwari JPMA. The Journal of the Pakistan Medical Association 52 (3), 111, 2002 | 35 | 2002 |
| Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy MA Waldrop, SA Moore, KD Mathews, BW Darbro, L Medne, R Finkel, ... Human mutation 43 (4), 511-528, 2022 | 32 | 2022 |
| Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial AL Mammen, AA Amato, MM Dimachkie, H Chinoy, Y Hussain, JB Lilleker, ... The Lancet Rheumatology 5 (2), e67-e76, 2023 | 29 | 2023 |
| Brain abscess AA Habib, T Mozaffar Archives of neurology 58 (8), 1302-1304, 2001 | 22 | 2001 |
| Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial PM Machado, MP McDermott, T Blaettler, C Sundgreen, AA Amato, ... The Lancet Neurology 22 (10), 900-911, 2023 | 18 | 2023 |
| Update on immune‐mediated therapies for myasthenia gravis AA Habib, G Ahmadi Jazi, T Mozaffar Muscle & Nerve 62 (5), 579-592, 2020 | 17 | 2020 |
| Randomized phase 2 study of ACE-083 in patients with Charcot-Marie-Tooth disease FP Thomas, TH Brannagan III, RJ Butterfield, U Desai, AA Habib, ... Neurology 98 (23), e2356-e2367, 2022 | 16 | 2022 |
| Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG symptoms PRO A Regnault, T Morel, C de la Loge, F Mazerolle, HJ Kaminski, AA Habib Neurology and therapy 12 (5), 1573-1590, 2023 | 13 | 2023 |
| Addressing outcome measure variability in myasthenia gravis clinical trials JT Guptill, M Benatar, V Granit, AA Habib, JF Howard Jr, C Barnett-Tapia, ... Neurology 101 (10), 442-451, 2023 | 13 | 2023 |
| Design and statistical innovations in a platform trial for amyotrophic lateral sclerosis M Quintana, BR Saville, M Vestrucci, MA Detry, L Chibnik, J Shefner, ... Annals of Neurology 94 (3), 547-560, 2023 | 13 | 2023 |
| Safety and outcomes with efgartigimod use for acetylcholine receptor‐positive generalized myasthenia gravis in clinical practice N Katyal, K Halldorsdottir, R Govindarajan, P Shieh, S Muley, P Reyes, ... Muscle & Nerve 68 (5), 762-766, 2023 | 12 | 2023 |
